Introduction
Cell growth is regulated by a number of interrelated signaling pathways whose combined eects are re¯ected in the activity of cell cycle regulatory molecules. Positive growth signals result from the action of cellular oncogenes such as tyrosine kinases, cellular ras, and a serine/threonine kinase cascade terminating with the activation of MAP kinases. Stress, cytokines, cell contacts, and a variety of other signals can restrict cell proliferation. Ultimately the action of these varying signaling systems is likely to converge upon the cyclins and associated proteins, whose action appears to control transition through various cell cycle check points.
For progression through G1 phase the activity of at least two sets of cyclin dependent kinases (cdk) appear to be critical. These kinases, typically cdk2 and cdk4, are activated by association with cyclin E or cyclin D respectively, but also require phosphorylation of a Thr residue in the T-loop (Thr160 for cdk2) and dephosphorylation of an amino terminal Tyr (Tyr15 for cdk2) and Thr (Gu et al., 1992) . Cdk activating kinase (CAK), composed of cyclin H and cdk7 (Fisher and Morgan, 1994) , is responsible for the activating phosphorylation at the T-loop Thr of many cdks. The activating dephosphorylation of cdk is performed by cdc25 or a related protein with dual Tyr/Thr phosphatase activity. Inhibition of cyclin-cdk kinase activity can result from the action of cdk-associated phosphatase (KAP) which is able to remove the phosphate from Thr160 of cdk2 (Hannon et al., 1994; Poon and Hunter, 1995) . The cyclin-cdk complex is also inhibited by phosphorylation at the amino terminal Tyr/Thr residues of cdks, which is catalyzed by wee1 (Coleman and Dunphy, 1994) or a related dual kinase.
Phosphorylation is not the only means of regulating the activity of cyclin-cdk complexes. A number of cdk inhibitory proteins have been identi®ed. p21
Waf1 is a cyclin inhibitory protein which was identi®ed as a p53 inducible gene (Waf1) (El-Deiry et al., 1993) , a cdk inhibitory protein (Cip1) (Gu et al., 1993; Harper et al., 1993; Xiong et al., 1993) or as a senescence speci®c gene product able to inhibit cell growth (Sdi1) (Noda et al., 1994) . Thus p21
Waf1 is produced when DNA damage induces p53 activity, resulting in a period of growth arrest during which the DNA damage can be repaired (Hunter, 1993) . p21
Waf1 is a prototype of a growing family of cyclin inhibitory proteins, including p57 kip2 (Lee et al., 1995; Matsuoka et al., 1995) and p27
Kip1 which plays an important role in tumor growth factor-b (TGFb) Toyoshima and Hunter, 1994) , cAMP (Kato et al., 1994) or rapamycin (Nourse et al., 1994) induced G1 growth arrest. These cyclin inhibitory proteins apparently act by binding to a broad range of cyclincdk complexes and inhibiting their kinase activity. Other cyclin inhibitory proteins (Ink family) are more speci®c in D type cyclin complexes they target. In addition to these growth inhibitory proteins whose mechanism of action is well characterized, there are other proteins involved in growth inhibition including the Gadd genes, induced by growth arrest and/or DNA damage. Gadd153 arrests cell cycle progression in G1 (Barone et al., 1994) , and gadd45 has been reported to inhibit cell proliferation .
These cell cycle regulatory proteins have provided clues to the mechanism of action of several growth inhibitory factors. TGF-b, for example, is known to stimulate the expression of certain cyclin inhibitory proteins including p21
Waf1 and p15
Ink4b
. In the case of TGF-b, the eects upon cyclins and associated proteins might be secondary to its ability to block the activity of cellular ras proteins, and thereby to disrupt the positive proliferative signal which ras activity initiates. This conclusion is based upon the fact that TGF-b induced G1 growth arrest can be overcome by the introduction of oncogenic ras, and because TGF-b action directly blocks ras activation in response to mitogenic treatment (Howe et al., 1993) . Previous work from this and other laboratories has shown that Prostaglandin A 2 (PGA2) is also able to inhibit cellular growth by altering the activity of a cyclin inhibitory protein, p21
Waf1 (Gorospe et al., 1996; Hitomi et al., 1996) . The mechanism of action of PGA2 is fundamentally dierent from that of TGF-b, however, since growth inhibition by PGA2 takes place without interfering with the activity of ras or its immediate downstream targets. Thus, PGA2 eciently blocks cell cycle progression of a broad range of cells, induces the expression of p21
Waf1
, and in so doing is able to keep G1 cyclin-cdk complexes from expressing kinase activity; but does so without interfering with the activation of ras, or ERK kinases .
Because of its unique ability to inhibit the kinase activity of G1 phase cyclin-cdk complexes, without altering the positive signal leading to ERK activation, the study of the molecular mechanism of PGA2-induced growth inhibition might provide a clue as to the normal means by which cellular oncogenes control the activity of cyclins and associated proteins, and thereby cell cycle progression. In this study we examined the expression levels, and the post-translational modi®cation status and/or activity of a panel of cell cycle regulatory molecules in PGA2 treated cells.
The results indicate that p21
Waf1 expression is indeed vital to the inhibitory action of PGA2. Surprisingly, however, this cyclin inhibitory protein functions not only by binding to active cyclin-cdk complexes and inhibiting their kinase activity, but perhaps even more eciently by binding to the cyclin-cdk complex prior to its activation in late G1, and preventing the phosphorylation event which is essential to its kinase activity.
Results

Eect of PGA2 on expression levels of growth regulatory proteins
We have reported that PGA2 abrogates the activation of the G1-phase cyclin-cdk complexes (cyclin D-cdk4 and cyclin E-cdk2) . This study was undertaken to determine the molecular mechanism for this suppression by analysing cellular proteins which might be involved in controling cdk activity. It was found that PGA2 treatment did not suppress the expression levels of cyclin E, cdk2 or cdk4 proteins. It did, however, suppress the elevation of cyclin D1 normally induced by serum stimulation of quiescent cells (Figure 1a ). PGA2 also inhibited the activating phosphorylation of cdk2, as indicated by the low level of the rapidly migrating form of cdk2 in Western analysis ( Figure 1a ). This faster migrating form of cdk2 is diagnostic of the phosphorylation at Thr160, which is required for kinase activity (Gu et al., 1992) . The reduction of cyclin D1 expression together with the suppression of phosphorylation of cdk2 are likely to be responsible, at least in part, for the low kinase activities of both cyclin D1-cdk4, and cyclin E-cdk2 in PGA2-treated cells .
The eect of PGA2 on growth inhibitory molecules was next examined. The increase in p21
Waf1 mRNA was detectable as early as 2 h after PGA2 addition, and continued to increase until reaching a plateau at 6 h after treatment (Figure 1b ). For comparison, NIH3T3 cells, which contain wild type p53 (Chen and Defendi, 1992; Chin et al., 1992; Price and Calderood, 1993) , were g-irradiated to induce a p53 dependent induction of p21
Waf1
. g-irradiation induced p21
Waf1 mRNA with similar kinetics, and to a similar extent as PGA2 treatment (Figure 1b) . On the other hand, p27 Kip1 , another cyclin inhibitory protein, was not aected by PGA2 treatment (Figure 1a) . Finally, the expression of Gadd45 was induced by PGA2 with kinetics similar to p21
Waf1 (Figure 1b) . The Gadd153 protein is normally expressed in serum starved cells, but became undetectable upon serum addition. PGA2 treatment, however, maintained the high Gadd153 protein expression even following serum addition to quiescent cells (Figure 1a) . Figure 1 PGA2 eect on expression of growth regulatory molecules. (a) Western blotting. NIH3T3 cells were made quiescent by serum starvation for 2 days. Cells were stimulated with 10% calf serum with or without 25 mM PGA2. Cell lysates were prepared either just before or 6 h and 9 h after the serum addition. Proteins (75 mg/lane) were separated by 12% SDS ± PAGE, and electrotransferred to a nitrocellulose membrane. The membrane was probed with anti-cdk2, cdk4, cyclin E, cyclin D, gadd153 and p27
Kip1 antibodies, as noted. (b) Northern blotting. Continuously growing NIH3T3 cells received 25 mM PGA2 or 5 Gy of g-irradiation. At the indicated times after treatment, total RNA was prepared and separated by formaldehyde-containing agarose gel electrophoresis. Equal loading was ensured by ethidium bromide staining for ribosomal RNA. The messages for p21
Waf1 and gadd45 were identi®ed with speci®c nucleotide probes p21
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Induction of p21
Waf1 and gadd45 mRNAs is independent of p53
Since p21
Waf1 and Gadd45 are p53 responsive genes (El-Deiry et al., 1993) , it was important to determine if PGA2 induction of these genes was dependent upon p53 protein. Initial studies were conducted to con®rm that the cells utilized in this study expressed wild type p53 activity. After g-irradiation of NIH3T3 cells the p53 protein levels were transiently increased as determined by Western blot analysis (Figure 2a) . girradiation also induced the expression of a factor able to bind to and alter the mobility of an oligonucleotide with the p53 binding consensus sequence. The complex with retarded mobility was identi®ed as containing p53 by the fact that it was further retarded following incubation with a p53 antibody (Figure 2b ). In addition, a luciferase reporter gene driven by a consensus p53 responsive promoter was elevated by g-irradiation and camptothecin (another DNA damaging agent and p53 inducer; Figure 2c ). All these data indicate NIH3T3 cells express wild type p53 protein, in good agreement with previous immumological studies (Chen and Defendi, 1992; Chin et al., 1992; Del Sal et al., 1995; Price and Calderood, 1993) .
Next we tested whether PGA2 treatment was able to induce p53 activity. While g-irradiation induced p53 protein transiently as detected by Western blotting, PGA2 did not signi®cantly induce p53 protein ( Figure  2a) . Little or no increase in binding to a p53 consensus oligonucleotide was detected with a gel mobility shift assay in PGA2 treated cells (Figure 2b ), and PGA2 failed to induce luciferase activity in cells transfected with a p53 responsive reporter gene plasmid ( Figure  2c ). These data indicate that PGA2 had little ability to stabilize or activate p53 protein. The induction of p21 Waf1 and Gadd45 messages by PGA2 in NIH3T3 cells (Figure 1b) , therefore, apparently occurred without induction of p53 activity.
To con®rm that PGA2 can induce p21 Waf1 and Gadd45 independently of p53, we next analysed MDAHO41 cells, which are genetically de®cient in p53 activity. For comparison, p53 containing NPC11 cells, which were derived from MDAHO41 cells by the introduction of a functional p53 gene under the control of its native promoter (Agarwal M and Stark GR unpublished data) , were also tested. Untreated MDAHO41 cells expressed low levels of p21 Waf1 message, and extremely low levels of gadd45 message. In these p53 de®cient cells PGA2 induced low levels of gadd45 message, and high level of p21 Waf1 message ( Figure 2d ). The p53-containing NPC11 cells expressed higher basal levels of p21
Waf1 and gadd45 messages than the p53 de®cient parental line, and each message was further induced by treatment with PGA2 ( Figure 2d ). Furthermore, when the p53 de®cient MDAHO41 cells were treated with 35 mM PGA2 for 24 h, the labeling index was decreased to the same extent (from 50% in non-treated cells to 20% following treatment) as with MRC5 cells (human diploid ®broblasts possessing wild type p53). These data con®rm that wild type p53 is not required for p21 Waf1 and gadd45 induction or growth inhibition by PGA2; consistent with data previously reported by others (Gorospe et al., 1996) .
PGA2 increased p21
Waf1 associating with cdk2
As indicated previously, the activity of cyclin E-cdk2 is eliminated by treatment with PGA2 . To determine if p21 Waf1 was responsible for this inactivation, their association together was tested. DNA binding activity of p53 protein after PGA2 treatment was determined by EMS assay. The nuclear extracts were made at the indicated times after treatment with 25 mM PGA2 or 5 Gy girradiation. Extracts were incubated with an end-labeled consensus p53 binding double stranded oligo DNA. To induce the super shift, an aliquot of the mixture was further incubated with anti-p53 Ab (Pab421). The complexes were separated by native polyacrylamide gel electrophoresis and detected by autoradiography. (c) Reporter gene assay for p53 transactivation activity. Rapidly growing NIH3T3 cells were co-transfected with expression vectors using the calcium-phosphate method. A RSV promoter driven b-galactosidase plasmid was transfected together with a p53 reporter construct (p53ConA-Luc). The next day cells were treated with 25 mM PGA2, 5 Gy of g-irradiation or 500 ng/ ml of camptothecin. After 20 h of treatment the cells were harvested and enzyme activity of b-galactosidase and luciferase were determined. (d) PGA2 induction of p21
Waf1 and gadd45 mRNA in a p53 negative cell. Cycling MDAHO41 cells (®broblasts derived from Li-Fraumeni syndrome patient possessing no functional p53 protein) were treated with 25 mM PGA2. After 20 h, total RNA was extracted and mRNA for p21
Waf1 or gadd45 were detected by Northern blotting. Actin mRNA was also detected as an internal control. NPC 11 cells were derived from MDAHO41 cells by transfection of a fully functional p53 gene whose expression was controlled by the native promoter, and were analysed as above p21
Waf1 inhibits activation of cdk2 M Hitomi et al Cellular cdk2 was immunoprecipitated with anti-cdk2 antibody, after which the co-precipitated proteins were separated by SDS ± PAGE and analysed by Western blotting with an anti-p21
Waf1 antibody. The amount of p21
Waf1 associated with cdk2 increased after PGA2 treatment ( Figure 3a , lanes 2 and 3, and lanes 4 and 5). In similar analyses, the amount of p27
Kip1 associating with cdk2 was found to be high in serum starved cells ( Figure 3a , lane 1), consistent with its proposed role in maintaining quiescence . After serum stimulation, however, cdk2-associated p27 Further study, however, raised questions about the role of p21
Waf1 in blocking cdk activity. In g-irradiated cells ( Figure 3a , lane 7), even though the level of p21
Waf1 associated with cdk2 was higher than in PGA2 arrested cells (Figure 3a , lane 5 or 3), the kinase activity of cdk2 prepared from g-irradiated cells was almost the same as that from non-treated cells ( Figure  3a , lanes 4 and 7). The association of p21
Waf1 with cyclin E-cdk2 could not, therefore, completely account for the reduction in kinase activity. It was therefore necessary to consider other mechanisms of inactivating cdk2 in PGA2 treated cells, such as the inhibitory phosphorylation at the amino terminal Tyr residue, the suppression of the activating phosphorylation at Thr160, or disruption of the association between cdk2 and cyclin E.
Eect of PGA2 treatment on cdk2 phosphorylations and complex formation
The degree of phosphorylation on Tyr15 of cdk2 was determined by Western blotting of a cdk2 immunoprecipitate using an anti-phosphotyrosine antibody, since Tyr15 is the major phosphorylated tyrosine residue in cdk2 (Gu et al., 1992) . Phosphotyrosine content of cdk2 was slightly decreased by PGA2 treatment (Figure 3b ). This change could not explain the decreased activity of cdk2 because the phosphorylation at Tyr15 is inhibitory for cdk2 activity (Gu et al., 1992) . When cyclin E immunoprecipitates were subjected to Western blotting using anti-cdk2, comparable amounts of cdk2 were detected in either serum starved cells, serum stimulated cells, or cells stimulated with serum in the presence of PGA2 (Figure 3b ), indicating that PGA2 did not inhibit cyclin E association with cdk2.
Immunoprecipitates of cdk2 reprobed with anti-cdk2 antibody in Western analyses showed cdk2 to migrate as a doublet. As shown previously, the slowly migrating form is not phosphorylated at Thr160 and therefore inactivate as a kinase, while the faster migrating form is phosphorylated at this residue and active (Gu et al., 1992) . As expected, in serum starved cells where cdk2 was inactive, the majority of cdk2 existed as the slowly migrating form. In serum stimulated cells which had progressed to late G1 phase, the proportion of the faster migrating form increased along with the kinase activity associated with the cdk2 immunoprecipitate (Figure 3a and b). This serum-induced Thr160 phosphorylation of cdk2 was blocked by prior PGA2 treatment, as was its kinase activity. Interestingly, the decreased levels of the faster migrating, Thr160 phosphorylated form of cdk2 was the biochemical parameter which correlated most closely with the inhibition of kinase activity of cdk2 in all conditions tested. As noted above, the amount of p21
Waf1 which associated with cdk2 could not completely account for the reduction of kinase activity (Figure 3a ).
PGA2 did not inhibit CAK activity
In order to determine why phosphorylation of Thr160 failed to take place following PGA2 treatment, the eect of PGA2 treatment upon the kinase responsible for this phosphorylation, CAK (Fisher and Morgan, Figure 3 Eects of PGA2 on cdk2 associating molecules and post-translational modi®cation. (a) Cdk2 was immunoprecipitated from NIH3T3 cells which had been made quiescent by serum starvation for 2 days (lane 1), quiescent cells restimulated with 10% serum without or with 25 mM PGA2 for 10 h (lanes 2 and 3, respectively), asynchronous cells in logarithmic phase (lane 4), asynchronous cells treated with PGA2 for 24 and 10 h (lanes 5 and 6, respectively), and asynchronous cells 6 h post 5 Gy girradiation (lane 7). Each immunoprecipitate was analysed for histone H1 kinase activity. The same immunoprecipitates were analysed by Western analysis using anti-cdk2, p21
Waf1
, and p27
Kip1 antibodies. (b) Cdk2 or cyclin E was immunoprecipitated from quiescent cells (0 h after serum), serum stimulated late G1 cells (10 h after serum stimulation), or from PGA2 treated G1 arrested cells (10 h after simultaneous serum and PGA2 addition). Separate aliquots of the precipitate was assayed for histone H1 kinase activity, or were subjected to Western blot analysis with anti-cdk2, anti-phosphotyrosine, or anti-p21
Waf1 antibody. The anti-phosphotyrosine blot was followed by anti-cdk2 blot after stripping o as described in Materials and methods. Using immunoglobulin bands as internal landmarks, two ®lms from each of these blots were superimposed, and the anti-phosphotyrosine positive bands corresponding to cdk2 bands were identi®ed. The position of cdk2 protein is indicated by arrows in the antiphosphotyrosine immunoblot. The thick bands below the cdk2 bands in phosphotyrosine blot were the signals from immunoglobulin light chain used for immunoprecipitation p21
Waf1 inhibits activation of cdk2 M Hitomi et al 1994), was studied. To determine if PGA2 had a direct inhibitory eect upon the kinase activity of CAK, CAK protein was immunoprecipitated and its kinase activity was determined using GST-cdk2 as a substrate. PGA2 up to 100 mM was added in vitro directly to the kinase assay mixture, and found to have no eect upon CAK activity (data not shown). Similarly, PGA2 did not directly inhibit cdk2 kinase activity in vitro (data not shown). An analysis was next performed to determine if CAK activity was reduced in PGA2-treated cells. CAK immunoprecipitated from PGA2-treated cells showed similar activity as that from non-treated cells after up to 10 h of treatment (Figure 4a) . PGA2, therefore, did not apparently interfere with the activity of CAK in vivo, either. For comparison, the same lysates used above for CAK analysis were subjected to a variety of other determinations. In these lysates, as in the others described above, cdk2 kinase activity as well as the phosphorylation of cdk2 Thr160 was suppressed by PGA2 treatment (Figure 4a ). Thus, PGA2 suppressed both cdk2 phosphorylation and activation without inhibiting the upstream activating kinase, CAK. Finally, the intracellular localization of cyclin H and cdk7, components of CAK, might be an indicator of its accessibility to the cyclin E-cdk2 complex. When the cells were stained with anti-cdk2, anti-cdk7, and anticyclin H at 6 and 10 h after the serum stimulation in the presence or absence of PGA2, all the antigens were detected in nuclei at all time points in all cells (data not shown). PGA2, therefore, did not induce a physical separation of CAK from cdk2 within the cell. Thus, there is no indication that the lack of phosphorylation of cdk2 Thr160 is due to the inactivity or inaccessibility of CAK.
Kinetic analysis of p21
Waf1 induction and cdk2 phosphorylation Thus, PGA2 did not inactivate cdk2 by inhibiting the activating kinase (CAK) or simply by promoting the association of p21
Waf1 with the active cdk2-cyclin E complex. To gain further insight into the mechanism of this inhibition, therefore, a kinetic analysis of PGA2 action was undertaken. It has been shown previously that PGA2 is inhibitory to cell cycle progression when added within 6 h of serum addition to quiescent NIH3T3 cells . Analysis of the same lysates utilized above in studies of CAK activity indicated that the majority of the phosphorylation of Thr160 in cdk2 takes place between 6 and 10 h after serum addition (Figure 4a ). To more critically analyse the timing of cdk2 phosphorylation and activation, the relative intensity of the two cdk2 bands were determined by densitometry in those lysates. It was clear from this analysis (Figure 4b ) that the faster migrating, phosphorylated form of cdk2 increased at 8 h after serum stimulation, except in the PGA2-treated culture. In these same lysates the level of p21 Waf1 associating with cdk2 was found to be higher in PGA2 treated cells than in non-treated cells at 6, 8 and 10 h after serum stimulation (Figure 4a ). Importantly, the increased level of p21
Waf1 associating with cdk2 was readily detectable in PGA2-treated cells at 6 h after serum addition (Figure 4a) , even before the majority of cdk2 Thr160 phosphorylation had taken place ( Figure  4b ). The fact that p21
Waf1 was induced prior to the activating phosphorylation of cdk2 made it possible that the p21
Waf1 had associated with the inactive cdk2 and prevented its activation.
A kinetic analysis was therefore undertaken to determine if the p21
Waf1 associated with cdk2 might be responsible for the inhibition of Thr160 phosphorylation (the biochemical parameter which correlated the best with its lack of activity in PGA2-treated cells; Figure 3a ). As indicated above, phosphorylation of cdk2 at Thr160 took place between 6 and 10 h after the serum restimulation (Figure 4b ). Serum deprived and restimulated cells were therefore treated with PGA2 before (5 h after serum addition) or during (8 h after serum addition) this cdk2 phosphorylation process. Then, after further incubation, the resulting cells were examined for cdk2 kinase activity, phosphorylation of cdk2 Thr160, and the level of p21
Waf1 associating with cdk2. Figure 4 The eects of PGA2 on CAK and cdk2. (a) CAK was immunoprecipitated using anti-cdk7 antibody from NIH3T3 cells at various times after serum stimulation of quiescent cells in the presence or absence of PGA2. Kinase activity of CAK was determined using a GST-cdk2 fusion protein as a substrate. From the same lysate cdk2 was also immunoprecipitated and the kinase activity for histone H1 analysed. The same cdk2 immunoprecipitates were analysed by Western blotting using anti-cdk2, and p21
Waf1 antibody. As expected, the histone kinase activity of cdk2 had been inhibited by PGA2 treatment. (b) Densitometric analysis of cdk2. The proportion of cdk2 non-phosphorylated and phosphorylated at Thr160 in cdk2 Western blot (panel a) was analysed densitometrically p21
Waf1 inhibits activation of cdk2 M Hitomi et al When PGA2 was added to the culture after the activating phosphorylation of cdk2 had already started (8 h after the serum addition, Figure 5 , lanes 5 and 6), the phosphorylated form of cdk2 was present in similar amounts compared to cells without added PGA2 ( Figure 5, lane 2) ; and the cdk2 complex exhibited high levels of kinase activity. This was the case when the cells were analysed at either 2 or 5 h subsequent to the addition of PGA2 (Figure 5 , lanes 5 and 6, respectively). The maintenance of high levels of the active form of cdk2 at 5 h after PGA2 addition indicated that PGA2 had not induced dephosphorylation of cdk2. On the other hand, when PGA2 was added to cultures at 5 h after serum addition, prior to phosphorylation of cdk2, the phosphorylation of cdk2, together with kinase activity, was blocked ( Figure 5 , lane 4). p21
Waf1 was associated with cdk2 at comparable high levels in all the determinations described above. These data support the possibility that the activation of cdk2 is blocked not because the activating kinase is inactive or sequestrated from cdk2, but because PGA2 had stimulated p21
Waf1 levels prior to the activating phosphorylation of Thr160 had taken place. The induced p21
Waf1 which then associated with cdk2 inhibited the subsequent activating phosphorylation. Interestingly, in those cells treated with PGA2 8 h after serum addition, the cdk2 activity was only partially inhibited despite the fact that the level of p21 Waf1 associating with cdk2 was comparable to those of cells treated with PGA2 earlier, where the cdk2 kinase activity was completely inhibited ( Figure 5 , lanes 5, 6 and 3, 4, respectively). This indicates that while p21 Waf1 does inhibit the activity of the phosphorylated complex, this inhibition is incomplete in PGA2-treated cells. Complete inhibition is observed when similar amounts of p21
Waf1 associate with cdk2 prior to the activating phosphorylation.
Activation of cdk2 in p21
Waf1 negative cells
In order to provide support for our model, that p21
Waf1 is able to block activation of cdk2 following PGA2 treatment, analyses were performed upon cells derived from a p21 Waf1 knockout mouse embryo. In asynchronously proliferating NIH3T3 cells, treatment with 25 mM PGA2 for 24 h eciently blocked proliferation and reduced the proportion of the activated form of cdk2 (Figure 6 ), as was observed in quiescent cells.
When the proliferating p21
Waf17/7 cells were subjected to this same analysis, 25 mM PGA2 failed to eect the activation of cdk2; there was no reduction in the proportion of the more rapidly migrating, activated form of cdk2 (Figure 6) . Moreover, the cdk2 kinase immunoprecipitated from 25 mM PGA2 treated p21
Waf17/7 cells was as active as that from non-treated cells. This observation demonstrates that p21
Waf1 is required for PGA2 to reduce the activated form of cdk2 and to suppress its kinase activity. This result provides direct biological con®rmation to the model presented above.
Biological signi®cance of p21
Waf1 in PGA2 growth suppression It was next important to relate the biochemical eects of PGA2 treatment on the p21
Waf17/7 cells to the biological consequences of that treatment. For this analysis the p21 Waf17/7 cells were compared to cells from a litter mate p21 Waf1+/+ embryo. A dose response analysis was conducted to determine the concentration Figure 5 Phosphorylation of cdk2 Thr160, cdk2 kinase activity, and p21
Waf1 expression. NIH3T3 cells were made quiescent by serum starvation for 2 days prior to restimulation with 10% calf serum. At the indicated time after serum addition PGA2 was added to the culture. The cells were then harvested at the indicated times after serum addition. Cdk2 was immunoprecipitated and its kinase activity was determined using histone H1 as a substrate. The same immunoprecipitates were analysed by Western blotting using anti-cdk2 and anti-p21
Waf1 antibodies Figure 6 Eect of PGA2 on Thr160 phosphorylation and activity of cdk2 in p21 Waf17/7 cells. (a) Western blotting.
Rapidly growing NIH3T3 cells and p21
Waf17/7 mouse embryonic ®broblast were treated with 25 mM of PGA2 for 24 h. Cell lysates were made and proteins (75 mg/lane) were subjected to Western analysis with anti-cdk2. Cdk2 was immunoprecipitated and its kinase activity was determined using GST-Rb as a substrate. (b) Densitometric analysis of cdk2. Cdk2 Western blot of panel a was analysed densitometrically p21
Waf1 inhibits activation of cdk2 M Hitomi et al of PGA2 required to inhibit proliferation in each of these two cell lines. The concentration of PGA2 required to block proliferation of the p21 Waf17/7 cells was considerably higher than that required to inhibit cells from the p21 Waf1+/+ embryo (Figure 7a ). This dierence in PGA2 sensitivity in these two cell populations clearly indicates that p21
Waf1 plays an important biological role in growth inhibition by PGA2. The Thr160 phosphorylation status of cdk2 in each of these two cell lines following treatment with the varying concentrations of PGA2 was next determined. In the p21
Waf1+/+ cells, PGA2 reduced the proportion of activated cdk2 in direct proportion to its ability to inhibit cell growth (Figure 7b,c) . This could be clearly visualized when the ratio between the unphosphorylated and phosphorylated forms of cdk2 was plotted against PGA2 concentration and compared to growth inhibition (Figure 7c ). At between 10 and 15 mM PGA2 both the phosphorylation of cdk2 and cellular proliferation were reduced dramatically. This result is consistent with the possibility that the primary inhibitory eect of PGA2 in these cells at minimal inhibitory concentrations is its ability to block activation of cdk2. On the other hand, the proportion of active cdk2 from p21 Waf17/7 cells was not aected by PGA2 treatment (Figure 7b and c) .
The growth of p21 Waf17/7 cells, however, was suppressed at higher concentrations of PGA2 (20 mM or higher). This growth inhibition did not result from reduction of cdk2 phosphorylation since at no concentration tested was cdk2 phosphorylation inhibited. Furthermore, the kinase activity of cdk2 was not suppressed even at 25 mM of PGA2 (Figure 6 ). Therefore, it is likely that at higher concentrations PGA2 targeted another molecule required for proliferation. Since cyclin D1 expression level was reduced in NIH3T3 cells following PGA2 treatment (Figure 1a) , we looked for cyclin D1 expression levels in the mouse embryo cells following treatment with varying concentration of PGA2. It was found that regardless of p21 Waf1 status of the cells, PGA2 suppressed the expression of cyclin D1 (Figure 7b) . Interestingly, PGA2-induced reduction of cyclin D1 levels occurred at approximately the same concentrations of PGA2 which induced growth inhibition of the p21
Waf17/7 cells (Figure 7a and b) . It is possible that growth inhibition in the p21
Waf17/7 cells resulted from inhibition of cyclin D1 expression at the higher PGA2 concentra- Figure 7 Eect of PGA2 on growth of p21 Waf17/7 and p21 Waf1+/+ mouse embryonic ®broblasts. (a) Dose-growth inhibition curves. p21 Waf17/7 (open circle) and p21 Waf1+/+ (closed circle) mouse embryonic ®broblasts were plated on coverslips and treated with varying concentrations of PGA2 for 24 h. For the last 1 h, cells were labeled with 3 H-thymidine and the labeling index was determined by autoradiography and analysis of at least 200 cells. The relative labeling index was calculated using mean values for non-treated cells as 100%. (b) Western blotting for cdk2 and cyclin D1. From parallel plates treated with increasing concentrations of PGA2 as above, cell lysate was made and the Thr160 phosphorylation status of cdk2 and expression levels of cyclin D1 were determined by Western blotting using speci®c antibodies. (c) Graphic expression of ratios of Thr160 phosphorylated/nonphosphorylated forms of cdk2. Density of each cdk2 bands (slowly and fast migrating forms) was quantitated using NIH Image following digital photography of the Western blots (panel b). The ratios between Thr160 phosphorylated (fast migrating) and nonphosphorylated (slowly migrating) forms of cdk2 were plotted against concentration of PGA2 Waf1 inhibits activation of cdk2 M Hitomi et al tion; although other proteins, including gadd proteins, might also be involved.
We conclude from these studies that p21 Waf1 is essential for PGA2 to block the activation of cdk2, according to the model presented above. In the cells tested, it appears that this eect is most sensitive to PGA2 treatment, and is responsible for growth inhibition at low PGA2 levels. Consequently, the p21 Waf17/7 cells were not inhibited in growth by PGA2 at limiting concentrations. As the concentration of PGA2 increased, however, other molecules limiting to growth become targets of PGA2 action. These other molecules are apparently induced by separate signaling pathways than those which lead to induction of p21 Waf1 , as higher concentrations were required for their induction. Nevertheless, as PGA2 concentrations were increased other molecules become growth inhibitory. Cyclin D1 appears to be an excellent candidate for the market targeted by PGA2 at 25 mM PGA2 in p21 Waf17/7 cells, since it is exactly at this concentration that its expression becomes sensitive to PGA2 action. We have not, however, ruled out the involvement of other growth inhibitory molecules at higher PGA2 levels.
Discussion
We reported previously that PGA2, an antiproliferative prostaglandin, inhibits the activation of G1 phase cyclin-cdk molecules and blocks proliferation without altering the activity of cellular ras or ERK kinases (elements of the positive proliferative pathway) . This study was undertaken to determine the molecular basis for the inhibition of cyclin-cdk activity. PGA2 was found to induce p21 Waf1 , a cdk inhibitor, independently of p53. In addition, PGA2 was shown to suppress expression levels of cyclin D1, and to induce the growth inhibitory molecules, gadd45 and gadd153.
The induction of p21 Waf1 was particularly interesting as physical binding of this molecule has been shown to directly inhibit the kinase activity of a broad range of cyclin/cdk complexes . Further studies were, therefore, performed to analyse the involvement of p21 Waf1 in suppression of cdk2 activity. Signi®cantly, it was found that the level of p21
Waf1 associating with cdk2 did not correlate in all cases with the degree of suppression of kinase activity of cdk2. The parameter which correlated best with cdk2 kinase activity was the phosphorylation status of Thr160, as judged by the electrophoretic mobility shift of the cdk2 protein (Gu et al., 1992) . CAK, the kinase responsible for the Thr160 phosphorylation of cdk2, was not inhibited by PGA2 in in vitro or in vivo. A kinetic analysis of the association of p21
Waf1 with cdk2 demonstrated that the level of p21
Waf1 associating with cdk2 increased prior to the activating phosphorylation of cdk2. Therefore, it was possible that this early elevation of p21
Waf1 associating with cdk2 might have prevented the phosphorylation of Thr160 in PGA2 treated cells. Signi®cantly, it was shown that if the p21 Waf1 became associated with cdk2 following its activating phosphorylation, kinase activity was not completely inhibited in these cells. This kinetic observation is important because it predicts that the check point that depends on p21
Waf1
, like the G1 check point for g-irradiation (Brugarolas et al., 1995; Deng et al., 1995) , is most likely de®ned by the temporal relationship between cdk phosphorylation by CAK and induction of p21
. Indeed, the PGA2 G1 arresting point that we previously reported is very closely related to the point when Thr160 phosphorylation of cdk2 takes place.
To verify the above model, studies were undertaken in p21
Waf1 de®cient cells. If, as predicted, PGA2 inhibits the activation of cdk2 by inducing p21
Waf1 which associates with cdk2 prior to the activating phosphorylation, then in p21
Waf17/7 cells, PGA2 should not be able to interfere with the normal activating phosphorylation of cdk2 and the development of its kinase activity. This prediction was veri®ed when PGA2 failed to alter the activity and the Thr160 phosphorylation status of cdk2 in p21 Waf17/7 cells. The fact that p21 Waf17/7 ®broblasts were more resistant to the antiproliferative action of PGA2 than p21
Waf1+/+ , together with the observation that growth suppression in p21
Waf1+/+ cells correlated well with the degree and timing of cdk2 phosphorylation, indicates that p21 Waf1 dependent suppression of cdk2 activation is critical for the antiproliferative activity of PGA2.
To our knowledge, this study is the ®rst in vivo evidence to suggest that p21
Waf1 is able to suppress cdk2 activity by interfering with the activating phosphorylation at Thr160 without inhibition of CAK activity per se. The biochemical basis for this observation, however, has been established. It has been reported that p21
Waf1 binding to cdk2 can inhibit the phosphorylation of cdk2 by CAK in vitro (Aprelikova et al., 1995) . In addition, the crystal structure of the cyclin Acdk2-p27kip1 ternary complex also predicts, by analogy, that p21 Waf1 binding to the cyclin-cdk2 complex may block the access of CAK to Thr160 (Russo, 1996) .
At increased concentrations of PGA2, however, the growth of p21 Waf17/7 cells was also suppressed. Initial observations identi®ed cyclin D1 and Gadd proteins, in addition to p21 Waf1 , as growth regulatory molecules in¯uenced by PGA2. The suppression of cyclin D1 was observed in all the cells treated. Its suppression pro®le corresponded well with growth suppression of PGA2 treated p21 Waf17/7 cells. Cyclin D-associated kinase activity is required to overcome the growth inhibitory activity of the retinoblastoma protein (Rb) (ConnellCrowley et al., 1997) . The ability of PGA2 to suppress cyclin D1 elevation might, therefore, be sucient to suppress growth of the cells even if they are defective in p21
. Interestingly, a higher concentration of PGA2 was required to suppress cyclin D1 expression than to induce p21
Waf1 synthesis. This dierence suggests that PGA2 induces growth arrest by altering multiple signaling pathways which separately eect these two proteins.
Protein phosphorylation status is the result of a balance between the actions of kinases and phosphatases. Since CAK activity was not altered by PGA2, the ability of PGA2 to accelerate the dephosphorylation of cdk2 at Thr160 was evaluated; even though the studies in p21
Waf17/7 cells clearly indicated that it was the initial phosphorylation, not dephosphorylation, which was blocked by PGA2 action. PGA2 was added to the culture 8 h after serum stimulation, when the phosphorylation of Thr160 had already begun. The PGA2 remained on the culture for an additional 5 h, after which cdk2 from treated culture and untreated control cultures was compared and found to be phosphorylated to a similar extent ( Figure 5 ). This indicated that PGA2 did not stimulate dephosphorylation of cdk2. The phosphatase, KAP, which dephosphorylates cdk2 and cdc2 (Poon and Hunter, 1995) can dephosphorylate Thr160 of monomeric cdk2 but not the cdk2 bound to cyclin A (Poon and Hunter, 1995) . In the NIH3T3 cells we used in this study, cdk2 was associated with cyclin E throughout G0 to S phase. It is, therefore, unlikely that KAP could dephosphorylate cdk2 in these cells. On the other hand, PPA1 can dephosphorylate 160 phospho-Thr of both bound and unbound cdk2 (Poon and Hunter, 1995) . The fact that PGA2 failed to accelerate dephosphorylation of Thr160 indicated that PGA2 did not stimulate PPA1 activity. p27 Kip1 has been implicated in the down-modulation of cdk activity during growth arrest induced by TGF-b (ReynisdoÂ ttir et al., 1995) , cAMP (Kato et al., 1994) , or rapamycin (Luo et al., 1996; Nourse et al., 1994) . Upon TGF-b treatment, p15 Ink4b is induced and replaces p27
Kip1 in the cyclin D-cdk4 complex. The released p27
Kip1 then is able to bind to cdk2 and suppresses cdk2 kinase activity (reynisdoÂ ttir et al., 1995) . In human keratinocytes arrested in G1 by TGFb, both p27
Kip1 and p21 Waf1 associating with cdk2 are increased . In PGA2 treated cells, however, p27
Kip1 associating with cdk2 is as low as in the non-treated cells. This suggests that p27
Kip1 is not involved in suppression of cdk2 activity during PGA2 induced growth arrest.
In this study we observed a number of eects of PGA2 treatment. Our kinetic studies, however, suggested that the rapid induction of p21 Waf1 by PGA2 prior to Thr160 phosphorylation of cdk2 might block that phosphorylation and thereby its activity. This prediction was veri®ed by the fact that PGA2 was unable to block activation of cdk2 in p21 Waf17/7 cells. We, therefore, propose that one of the means by which p21
Waf1 blocks the activity of cyclin dependent kinases, and hence it suppresses cell growth is by inhibiting an activating phosphorylation by CAK. This represents the identi®cation of a novel means by which cyclin inhibitory proteins control the activity of cyclin dependent kinases, and thereby cell cycle progression.
Materials and methods
Materials
The consensus p53 binding palindromic oligonucleotide (5'-GGACATGCCCGGGCATGTCC-3') (Funk et al., 1992) was synthesized by Operon Technologies (Alameda, CA). Anti-p53 antibody (mouse monoclonal, Pab421) was obtained from Oncogene Science (Cambridge, MA). Rabbit polyclonal anti cdk2 (M2), anti-cdk7 (C-19), anticyclin E (M-20), anti-cyclin H (C-18), anti-gadd153 (F-168) antibodies, anti-cyclin D1 (mouse monoclonal, 72-13G), anti-p21 Waf1 (goat polyclonal, C-19), and GST-Rb fusion protein were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). A mouse monoclonal anti-phosphotyrosine (clone 4G10) was obtained from Upstate Biotechology (Lake Placid, NY). The plasmid containing p21 Waf1 cDNA (ATCC 79924) was obtained from ATCC. The Gadd45 cDNA containing plasmid was generously provided by Dr Albert J Forence Jr (Hollander et al., 1993) . Glutathione S transferase-cdk2 fusion protein (GSTcdk2) expression vector was a generous gift from Dr LiHue Tsai (Tsai et al., 1991 Cell culture and transient transfection NIH3T3 cells were maintained and synchronized by serum deprivation as described . MDAHO41 cells and NPEC11 cells were maintained as described (Agarwal et al., 1995) . p21
Waf17/7 and p21 Waf1+/+ mouse ®broblasts from litter mate embryos (generously provided by Dr Gregory J Hannon) and MRC5 cells (ATCC, Rockville, MD) were grown in 10% fetal calf serum, 100 unit/ml penicllin and streptomycin supplemented D-MEM. For 24 h PGA2 treatment, PGA2 containing medium was refreshed every 12 h. To determine the proportion of cells in S phase, cell grown on coverslips were pulsed with 2.5 mCi/ml of [methyl-3 H] thymidine (80 ci/mmol) (Amersham, Arlington Heights, IL) for the last 1 h of the culture. Fixed cells were autoradiographed, then more than 200 cells were counted and the labeling index was determined as described . For reporter gene experiments, NIH3T3 cells were grown to approximately 60% con¯uency. They were transfected with the p53 responsive reporter gene plasmid, p53ConA-Luc (30 mg/60 mm plate), a generous gift from Dr Jerry W Shay (Funk et al., 1992) , using the calcium phosphate precipitate method under 3% CO 2 atmosphere (Sambrook et al., 1989) . The cells were co-transfected with bgalactosidase expression vector driven by RSV promoter (20 mg/60 mm plate) to assess transfection eciency. One day after the transfection, cells were treated with 5 Gy of g-ray using a 137 Cs irradiator, 25 mM PGA2 or 500 ng/ml camptothecin and harvested 20 h thereafter. Luciferase activity was determined by luciferase kit (Promega, Madison, WI) using a microtiter plate luminometer (Dynatech Laboratories, Chantilly, VA). The activity of b-galactosidase was determined as described (Sambrook et al., 1989) . Luciferase activity was expressed relative to bgalactosidase activity.
Kinase assay, Western and Northern blotting
Cdk2 kinase asssay has been described , except in some assays, GST-Rb (0.5 mg/assay) was used as a substrate. Cdk7 kinase assay was done as cdk2 kinase assay except that GST-CDK2 (1 mg/assay) was used as substrate and that immunoprecipitation was performed in an excess of precipitating antibody; 100 mg of cytosol protein was incubated with antibody precoated protein A Sepharose beads (2 mg antibody/assay). To assess the direct eect of PGA2 upon cdk, immunoprecipitation was made from late G1 cells, and kinase activity was determined in the presence of varying concentration of PGA2. Kinase activity was determined by PhosphoImager using Image Quant (Molecular Dynamics, Sunnyvale, CA).
Proteins of cell lysate (lysed by cdk2 kinase buer) or immunoprecipitate was separated by SDS ± PAGE (T=12%), Waf1 inhibits activation of cdk2 M Hitomi et al transferred to a nitrocellulose membrane. The protein of interest was visualized by Western blotting as described . The protein was determined by Bradford method (Bio-Rad) keeping the detergent concentration below the tolerable limit as indicated in the manufacturer's instruction. To re-probe the blot with another antibody, the previous antibodies were stripped o by incubation with 65 mM Tris HCl, 100 mM 2-mercaptoethanol and 1% SDS for 30 min at 508C. The p21
Waf1 was identi®ed as an anti-p21
Waf1 immunoreactive band which comigrated with the immunoreactive, g-irradiation inducible 21 kDa band of NIH3T3 cell lysate . This was veri®ed by the absence of this band in lyasate form p21
Waf17/7 cells (data not shown). To determine the density of Western blot bands, an exposed ®lm was scanned with ScanMaker III run by Scan Wizard (Microtek, Redondo Beach, CA) at resolution of 300 d.p.i. and at 256 gray scale. The captured image was analysed by NIH Image (Version 1.56). For visualization of a density slice (Figure 4 and 6) , plot pro®le' function was used. To quantitate individual band (Figure 7) , a band of interest was encircled with`free hand' and size of area and mean density was determined using`Measure' function. The density of the band was calculated by multiplying size and mean density followed by subtracting the background. The background was determined using the same encircled area transposed to adjacent blank area of the band.
Northen blotting was performed as described elsewhere . The equal loading was monitored by the S18 and S28 ribosomal RNA¯uoresence intensity after ethidium bromide staining of the gel or by probing the blot for actin mRNA.
Gel electrophoresis mobility shift assay
Gel electrophoresis mobility shift assay was done as described (Price and Calderood, 1993) . Double stranded p53 protein binding consensus oligonucleotide was endlabeled by polynucleotide kinase as described (Maniatis et al., 1982) . The super shift was induced with 0.2 mg/assay of Anti-p53 antibody.
